Please assess the completion status of the following clinical trial:

Trial Title: A Study in Erectile Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* At least a 3-month history of erectile dysfunction (ED).~* Are able to read, understand and provide signed informed consent.~* Have an International Index of Erectile Function-Erectile Function (IIEF-EF) domain score that is greater than or equal to 17 and less than 26 at screening.~* Have been taking a maximum dose of sildenafil citrate (100 milligram \[mg\]), vardenafil (20 mg), or tadalafil (20 mg) on as needed basis for at least one month prior to screening.~* Anticipate having the same female sexual partner during the study who is willing to participate in the required number of sexual intercourse attempts and complete study measures during the study.~* Agree to make at least four sexual intercourse attempts during both the 4-week as needed run-in period and the 4-week non-drug run-in period.~* Agree not to use any other erectile dysfunction (ED) treatment, including herbal therapy during the 4-week non-drug, run-in, the double-blind treatment period, the open label period and for 96 hours after the end of the study.~Partner Inclusion Criteria:~* Are female and at least 18 years of age at screening.~* Anticipate having the same male study subject as her sexual partner during the study.~* Able to read, understand and provide signed informed consent.~* Agree to make the required number of sexual intercourse attempts with the male sexual study partner during the study.~* Willing to participate in recording responses to the treatment satisfaction scale.~Exclusion Criteria:~* Have an IIEF-EF domain score of greater than or equal to 26 at screening.~* Prior ineffective treatment with (or nonresponder to) any PDE5 Inhibitor~* Have previously used or are currently using any PDE5 inhibitor once daily.~* Present with ED caused by other primary disorders or ED caused by untreated/inadequately treated endocrine disease.~* Partner unwilling to complete all study requirements.~* History of radical prostatectomy or other pelvic surgery or penile implant, or a clinically significant penile deformity, in the opinion of the investigator~* Exhibit evidence of clinically significant renal insufficiency or hepatobiliary disease, or significant cardiac history as determined by the investigator~* Currently receive treatment with nitrates, cancer chemotherapy, or antiandrogens~* Have previously completed or withdrawn from this study or any other study investigating tadalafil for once-daily use.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2.5 milligram (mg) titrated to 5 mg Tadalafil (Type: ACTIVE_COMPARATOR): 2.5 mg for 4 weeks, followed by 5 mg for 8 weeks with option to continue treatment at 5 mg for an additional 4 weeks
- 5 mg Tadalafil (Type: ACTIVE_COMPARATOR): 5.0 mg for 12 weeks with option to continue treatment for additional 4 weeks
- Placebo (Type: PLACEBO_COMPARATOR): for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).